Summit Therapeutics
SMMT
93 hedge funds and large institutions have $60.4M invested in Summit Therapeutics in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 15 closing their positions.
1,170% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $165K
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
0.38% less ownership
Funds ownership: 5.01% → 4.63% (-0.38%)
7% less funds holding
Funds holding: 100 → 93 (-7)
31% less capital invested
Capital invested by funds: $87.7M → $60.4M (-$27.3M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$1.2M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$530K |
| 3 |
BlackRock
New York
|
+$408K |
| 4 |
Barclays
London,
United Kingdom
|
+$190K |
| 5 |
JP Morgan Chase
New York
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$6.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$482K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$350K |
| 4 |
Goldman Sachs
New York
|
-$303K |
| 5 |
Millennium Management
New York
|
-$293K |
SMMT Hedge Fund Activity: Q3 2023 in Review
93 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2023, worth a combined $60.4M — down 31% from $87.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SMMT and 8 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 34 added.
The largest buyer was Charles Schwab, adding an estimated $1.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.03M.
- 93 institutional investors held Summit Therapeutics (SMMT) as of Q3 2023, down from 100 in Q2 2023.
- Funds reported $60.4M of Summit Therapeutics stock for Q3 2023, down 31% quarter-over-quarter.
- 8 funds opened new Summit Therapeutics positions in Q3 2023 and 15 closed out, a net change of -7 holders.
- The largest Summit Therapeutics buyer in Q3 2023 was Charles Schwab, an estimated $1.2M added.
- The largest Summit Therapeutics seller in Q3 2023 was Baker Bros. Advisors, an estimated $6.03M sold.
Based on aggregated 13F filings for Q3 2023.